Phaseline

Companies › Green Valley (Shanghai) Pharmaceuticals

Green Valley (Shanghai) Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 4; Neurology; next expected readout Jun 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sodium Oligomannate Capsules (GV-971)
Modulator of gut microbiota and neuroinflammation
GLP1R, FFAR2Phase 4Alzheimer Disease; Alzheimer's DiseaseJun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05058040Sodium Oligomannate Capsules (GV-971)Phase 4Alzheimer DiseaseNeurologyJan 2025
NCT05181475Sodium Oligomannate Capsules (GV-971)Phase 4Alzheimer DiseaseNeurologyJan 2025
NCT05908695Sodium Oligomannate Capsules (GV-971)Phase 4Alzheimer's DiseaseNeurologyJun 2029

Targets

GLP1R (1) FFAR2 (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Innovent Biologics (Suzhou)

Companies built like this

Prilenia Ambros Therapeutics Cerevance CereMark Pharma MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.